flow trial semaglutide renal outcomes 2024 kidney Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial flow semaglutide trial Results from

95% CI, 0.680.84

Effect estimates remained robust when restricting to patients with available hemoglobin A1c and including it in the propensity score (Supplementary Table 23)

What Are the Official Missed Dose Rules and When Should You Skip or Take It

At month 5, I realized I hadnt thought about the medication in weeks

Patients exploring affordable compounded tirzepatide options often find that cash-pay pricing is more predictable and sometimes less expensive than insurance copays for the brand-name products

GLP-1 receptor agonists and risk of cancer in type 2 diabetes: an updated meta-analysis of randomized controlled trials